Paricalcitol and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Paricalcitol (paricalcitol), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Insulin, and have Nuclear magnetic resonance imaging abdominal.

The phase IV clinical study analyzes which people have Mobility decreased when taking Paricalcitol. It is created by eHealthMe based on reports of 1,275 people who have side effects when taking Paricalcitol from the FDA, and is updated regularly.

What is Paricalcitol?

Paricalcitol has active ingredients of paricalcitol. eHealthMe is studying from 1,278 Paricalcitol users. Check the latest studies of Paricalcitol.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,774 drugs and 1,633 conditions by eHealthMe. Check the latest studies of Mobility decreased.

On Jul, 20, 2026

1,275 people reported to have side effects when taking Paricalcitol.
Among them, 52 people (4.08%) have Mobility decreased.

Could Paricalcitol cause Mobility decreased?

Among these 52 people:

How long have people been on Paricalcitol when they have Mobility decreased? *

What is the gender of people who have Mobility decreased when taking Paricalcitol? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Mobility decreased when taking Paricalcitol? *

What are other drugs people take besides Paricalcitol? *

What are other side effects people have besides Mobility decreased? *

Pain In Extremity: 42 people, 80.77%
Weakness: 42 people, 80.77%
Renal Impairment (severely reduced kidney function): 38 people, 73.08%
Hypoaesthesia (reduced sense of touch or sensation): 37 people, 71.15%
Nephropathy (damage to or disease of a kidney): 37 people, 71.15%
Pneumonia: 37 people, 71.15%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 37 people, 71.15%
Sepsis (a severe blood infection that can lead to organ failure and death): 37 people, 71.15%
Cardiopulmonary Failure (cessation of normal circulation of the blood due to failure of the heart to contract): 37 people, 71.15%
Hypotonia (low muscle tone): 37 people, 71.15%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 5 people, 9.62%
Nuclear Magnetic Resonance Imaging Abdominal: 5 people, 9.62%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 3 people, 5.77%
Tenderness (pain or discomfort when an affected area is touched): 1 person, 1.92%
Swelling: 1 person, 1.92%
Polyarthritis (arthritis which involves 5 or more joints simultaneously): 1 person, 1.92%
Pituitary Tumor Benign: 1 person, 1.92%
Pain: 1 person, 1.92%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 1 person, 1.92%
Hypotension (abnormally low blood pressure): 1 person, 1.92%

* Approximation only. Some reports may have incomplete information.

Do you take Paricalcitol and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Paricalcitol:

Paricalcitol (1,278 reports)

Browse all side effects of Paricalcitol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,774 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,633 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Paricalcitol) and Paricalcitol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.